10x Genomics Inc - Ordinary Shares - Class A Forecast, price target & analysts
10x Genomics Inc - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation
10x Genomics Inc - Ordinary Shares - Class A Classifications & Recommendation:
10x Genomics Inc - Ordinary Shares - Class A Price Target
| Target Price | $14.83 |
| Price | $8.31 |
| Potential |
78.50%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target 10x Genomics Inc - Ordinary Shares - Class A 2026 .
The average 10x Genomics Inc - Ordinary Shares - Class A target price is $14.83.
This is
78.50%
register free of charge
$26.00
212.88%
register free of charge
$7.50
9.75%
register free of charge
|
|
| A rating was issued by 20 analysts: 8 Analysts recommend 10x Genomics Inc - Ordinary Shares - Class A to buy, 10 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the 10x Genomics Inc - Ordinary Shares - Class A stock has an average upside potential 2026 of
78.50%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 610.79 | 608.86 |
| 1.28% | 0.32% | |
| EBITDA Margin | -24.31% | -26.55% |
| 4.95% | 9.21% | |
| Net Margin | -30.43% | -30.53% |
| 29.37% | 0.32% |
17 Analysts have issued a sales forecast 10x Genomics Inc - Ordinary Shares - Class A 2025 . The average 10x Genomics Inc - Ordinary Shares - Class A sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an 10x Genomics Inc - Ordinary Shares - Class A EBITDA forecast 2025. The average 10x Genomics Inc - Ordinary Shares - Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 10x Genomics Inc - Ordinary Shares - Class A Analysts have issued a net profit forecast 2025. The average 10x Genomics Inc - Ordinary Shares - Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.52 | -1.52 |
| 30.28% | 0.00% | |
| P/E | negative | |
| EV/Sales | 1.17 |
18 Analysts have issued a 10x Genomics Inc - Ordinary Shares - Class A forecast for earnings per share. The average 10x Genomics Inc - Ordinary Shares - Class A EPS is
This results in the following potential growth metrics and future valuations:
10x Genomics Inc - Ordinary Shares - Class A...
Current 10x Genomics Inc - Ordinary Shares - Class A Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Apr 10 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Mar 04 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 14 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Apr 10 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Mar 04 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 14 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
